Jefferies starts Sunesis at buy

Jefferies & Co., Inc. analyst Adam Walsh started covering Sunesis Pharmaceuticals, Inc. with a buy rating and an $8 price target. Walsh believes 2007 could be a pivotal year for Sunesis, as multiple potential value-creating milestones are on tap. The company also boasts a robust pipeline of small molecule oncology product candidates as well as an experienced management team. Shares of the South San Francisco, Calif.-based clinical-stage biopharmaceutical company were up 5 cents, or 0.05%, at $4.96. (Nasdaq: SNSS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.